After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Peter M.

1 Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China 2 National Clinical Research Center for Skin and Immune Diseases, Peking University First ...

Lupus is an autoimmune condition that can cause pain, problems in multiple organs and systems of the body, inflammation, and complications that range from minor to life threatening. The body’s ...

Earlier tonight, Congress passed the Full-Year Continuing Appropriations and Extensions Act funding the government for the remainder of Fiscal Year 2025—through September 30, 2025-- at current funding ...

Promising active ingredient for lupus therapy Date: March 12, 2025 Source: University of Zurich Summary: Lupus is an autoimmune disease where the body's immune system attacks its own tissues and ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in psoriatic arthritis (PsA), the company has presented detailed data from ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO ...